Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $120
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice TargetHot
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $119 to $120.
Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $119 to $120.
